Triple-negative breast cancer: integrating molecular biology, therapeutic strategies, and phytochemical interventions

Triple negative breast cancer (TNBC) represents a clinically aggressive form of breast carcinoma distinguished by the lack of estrogen, progesterone, or HER2 receptors, which limits therapy options and poorer prognosis. This subtype exhibits considerable heterogeneity and is driven by multiple molecular signaling networks mTOR, Wnt, Notch, and NF-kB. Chemotherapy is primary treatment strategy, although new targeted treatment options and immunotherapies, including PARP and immune checkpoints, are polyphenols and flavonoids which can alter cancer pathways. In order to improve patient outcomes, subsequent therapies will focus on a combination of conventional and modern therapies that target the tumor microenvironment.